Histone Deacetylase Inhibitors: A Therapeutic Key in Neurological Disorders?

Abstract Understanding the contribution of imbalance in protein acetylation levels and dysfunction of transcription to neurodegenerative diseases provides the rationale for the use of epigenetic modulators such as histone deacetylase (HDAC) inhibitors to combat neurodegenerative conditions. It is no...

Full description

Saved in:
Bibliographic Details
Published in:Journal of neuropathology and experimental neurology 2018-10, Vol.77 (10), p.855-870
Main Authors: Ziemka-Nalecz, Malgorzata, Jaworska, Joanna, Sypecka, Joanna, Zalewska, Teresa
Format: Article
Language:English
Subjects:
Neurodegeneration
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Understanding the contribution of imbalance in protein acetylation levels and dysfunction of transcription to neurodegenerative diseases provides the rationale for the use of epigenetic modulators such as histone deacetylase (HDAC) inhibitors to combat neurodegenerative conditions. It is now widely recognized that various low-molecular weight HDAC inhibitors are broadly neuroprotective, preventing or delaying neuronal death and dysfunction in many rodent models of neurodegeneration. The beneficial effects result in part from modifications of histones and nonhistone proteins. This review describes evidence indicating that HDAC inhibitors have emerged as a promising new strategy in treating neurodegenerative disorders and summarizes treatment strategies from clinical trials currently underway.
ISSN:0022-3069
1554-6578
DOI:10.1093/jnen/nly073